Last reviewed · How we verify
AQAS
AQAS is a quality assurance system used by the CDC to monitor and ensure the accuracy of laboratory test results for infectious diseases.
AQAS is a quality assurance system used by the CDC to monitor and ensure the accuracy of laboratory test results for infectious diseases. Used for Laboratory quality assurance for HIV testing, Proficiency testing for infectious disease diagnostics.
At a glance
| Generic name | AQAS |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease Diagnostics |
| Phase | FDA-approved |
Mechanism of action
AQAS (Antiretroviral Quality Assurance System) is a proficiency testing and quality control program that evaluates laboratory performance in testing for HIV and other infectious diseases. It provides external quality assessment to help laboratories maintain high standards of accuracy and reliability in diagnostic testing.
Approved indications
- Laboratory quality assurance for HIV testing
- Proficiency testing for infectious disease diagnostics
Common side effects
Key clinical trials
- Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents
- Adherence to Antimalarial Drugs in Sierra Leone (NA)
- Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria (PHASE3)
- Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AQAS CI brief — competitive landscape report
- AQAS updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI